Oncolytics Total Assets vs Common Stock Analysis
ONCY Stock | USD 1.13 0.03 2.59% |
Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Total Assets and its Common Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.
Total Assets vs Common Stock
Total Assets vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Total Assets account and Common Stock. At this time, the significance of the direction appears to have strong relationship.
The correlation between Oncolytics Biotech's Total Assets and Common Stock is 0.66. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Common Stock in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Total Assets and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Oncolytics Biotech are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Assets i.e., Oncolytics Biotech's Total Assets and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.66 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Assets
Total assets refers to the total amount of Oncolytics Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Oncolytics Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Common Stock
Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 118.3 M in 2024, whereas Tax Provision is likely to drop slightly above 84.1 K in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 98.6K | 528K | 1.2M | 1.2M | Net Interest Income | 98.6K | 528K | 1.2M | 1.2M |
Oncolytics Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Oncolytics Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oncolytics Biotech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 30.5M | |
Total Current Liabilities | 12.9M | 2.7M | 2.7M | 3.9M | 4.2M | 3.9M | |
Total Stockholder Equity | (107.9K) | 24.8M | 36.1M | 26.5M | 27.6M | 17.8M | |
Property Plant And Equipment Net | 727.5K | 609.1K | 976.3K | 652K | 647K | 460.6K | |
Net Debt | (13.6M) | (30.8M) | (40.6M) | (11.3M) | (31.1M) | (29.6M) | |
Retained Earnings | (344.6M) | (367.1M) | (393.4M) | (418.3M) | (446.0M) | (423.7M) | |
Accounts Payable | 3.2K | 1.8K | 594K | 2.3M | 1.1M | 1.0M | |
Cash | 14.1M | 31.2M | 41.3M | 11.7M | 31.5M | 19.3M | |
Non Current Assets Total | 727.5K | 609.1K | 976.3K | 1.7M | 647.0K | 614.6K | |
Cash And Short Term Investments | 14.1M | 31.2M | 41.3M | 32.1M | 34.9M | 26.6M | |
Net Receivables | 2.1M | 89.7K | 866.1K | 521K | 15K | 14.3K | |
Common Stock Shares Outstanding | 22.1M | 40.3M | 53.5M | 58.0M | 67.6M | 71.0M | |
Liabilities And Stockholders Equity | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 30.5M | |
Non Current Liabilities Total | 6.9M | 6.9M | 7.1M | 6.9M | 7.0M | 7.4M | |
Other Current Assets | 2.7M | 2.4M | 2.8M | 3.0M | 3.2M | 3.4M | |
Other Stockholder Equity | 33.0M | 34.6M | 37.8M | 40.1M | 42.1M | 38.2M | |
Total Liab | 19.8M | 9.6M | 9.8M | 10.8M | 11.3M | 6.0M | |
Property Plant And Equipment Gross | 1.7M | 609.1K | 976.3K | 652K | 1.3M | 1.4M | |
Total Current Assets | 18.9M | 33.7M | 44.9M | 35.7M | 38.2M | 28.0M | |
Accumulated Other Comprehensive Income | 464.1K | 400.2K | 387.7K | 662K | 544K | 516.8K | |
Other Current Liab | 12.5M | 2.5M | 2.4M | 1.5M | 4.1M | 4.3M | |
Other Liab | 4.6M | 5.9M | 6.7M | 6.7M | 7.7M | 8.1M | |
Net Tangible Assets | (107.9K) | 24.8M | 36.1M | 26.5M | 30.5M | 32.0M | |
Common Stock Total Equity | 271.7M | 285.2M | 311.1M | 356.8M | 410.3M | 430.9M | |
Short Term Investments | 13.1M | 30.4M | 1.4M | 20.5M | 3.4M | 3.2M | |
Short Term Debt | 339.8K | 248.9K | 293.7K | 216K | 133K | 127.3K | |
Common Stock | 311.1M | 356.8M | 391.3M | 404.0M | 430.9M | 452.5M | |
Property Plant Equipment | 727.5K | 609.1K | 976.3K | 652K | 749.8K | 377.8K | |
Capital Lease Obligations | 506.3K | 402.1K | 654.8K | 373K | 423K | 288.3K | |
Current Deferred Revenue | (3.2K) | (1.8K) | (594K) | (1.1M) | (973.8K) | (925.1K) | |
Net Invested Capital | (107.9K) | 24.8M | 36.1M | 26.5M | 27.6M | 20.3M | |
Net Working Capital | 6.1M | 31.0M | 42.2M | 31.7M | 33.9M | 26.6M | |
Capital Stock | 311.1M | 356.8M | 391.3M | 404.0M | 430.9M | 399.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.Note that the Oncolytics Biotech information on this page should be used as a complementary analysis to other Oncolytics Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Oncolytics Stock analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Oncolytics Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Return On Assets (0.64) | Return On Equity (1.16) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.